The popularity of Viagra initially fueled a boom for pharma, but recent shifts present a complicated picture for those considering a stake. Generic versions are eroding profits, and continued legal battles add further difficulty to the landscape. While specific companies might still see gains from related services, the broader trajectory suggests a